1. |
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer, 2010, 127(12):2893-2917.
|
2. |
Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol, 2013, 33 Suppl 1:S79-S84.
|
3. |
Liu Y, Gao SJ, Du BX, et al. Association of IL-6 polymorphisms with hepatocellular carcinoma risk:evidences from a meta-analysis. Tumour Biol, 2014, 35(4):3551-3561.
|
4. |
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol, 2014, 26(1):54-74.
|
5. |
姚小健.替吉奥联合康莱特注射液治疗老年晚期胰腺癌临床观察.肿瘤基础与临床, 2015, 28(4):350-352.
|
6. |
史恩红, 徐梦, 王娜, 等.康莱特注射液对改善癌症晚期患者生存质量的临床观察.中国实用医药, 2015, 10(6):52-54.
|
7. |
Sansone P, Bromberg J. Environment inflammation and cancer. Curr Opin Genet Dev, 2011, 21(1):80-85.
|
8. |
Balkwill F, Mantovani A. Inflammation and cancer:back to Virchow? Lancet, 2001, 357(9255):539-545.
|
9. |
Karin M, Greten FR. NF-κB:linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 2005, 5(10):749-759.
|
10. |
刘徽, 朱波, 林治华. IL-6信号通路与肿瘤.细胞与分子免疫学杂志, 2011, 27(3):353-355.
|
11. |
万凌峰, 赵红兵, 薛博瑜.慢性肝脏炎症与肝癌关系的研究进展.世界华人消化杂志, 2014, 22(31):4757-4761.
|
12. |
Berasain C, Castillo J, Perugorria MJ, et al. Inflammation and liver cancer:new molecular links. Ann N Y Acad Sci, 2009, 1155:206-221.
|
13. |
Grzesiak JJ, Smith KC, Chalberg C, et al. TypeⅠcollagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells. Int J Gastrointest Cancer, 2005, 36(3):131-146.
|
14. |
Su YW, Xie TX, Sano D, et al. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase. PLoS One, 2011, 6(4):194-196.
|
15. |
姚庆华, 郭勇.薏苡仁甘油三醋康莱特治疗晚期恶性肿瘤患者机制研究进展.中国肿瘤临床, 2012, 39(16):1151-1154.
|
16. |
甘霖, 于镜泊, 张海青, 等.康莱特注射液在乳腺癌新辅助化疗中的作用.肿瘤, 2009, 29(3):283-285.
|
17. |
Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 2007, 317(5834):121-124.
|
18. |
Grivennikov SI, Greten FR, Karin M. Immunity inflammation and cancer. Cell, 2010, 140(6):883-899.
|
19. |
Serova M, Ghoul A, Benhadji KA, et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol, 2006, 33(4):466-478.
|
20. |
Calzado MA, Bacher S, Schmitz ML. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem, 2007, 14(3):367-376.
|
21. |
Olivier S, Robe P, Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents. Biochem Pharmacol, 2006, 72(9):1054-1068.
|
22. |
Kim YJ, Kim HC, Ko H, et al. Stercurensin inhibits nuclear factorka-ppaB-dependent inflammatory signals through attenuation of TAK1-TAB1 complex formation. J Cell Biochem, 2011, 112(2):548-558.
|
23. |
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflamma-tion. Nature, 2008, 454(7203):436-444.
|